Prostatic Artery Embolization

Prostatic Artery Embolization Market Outlook

The global Prostatic Artery Embolization (PAE) market is projected to reach approximately USD 500 million by 2035, growing at a robust CAGR of around 9.5% during the forecast period from 2025 to 2035. This notable growth can be attributed to several factors, including the increasing prevalence of prostatic diseases such as Benign Prostatic Hyperplasia (BPH) and prostate cancer, alongside advancements in embolization technologies. Furthermore, the rising awareness regarding minimally invasive procedures is driving the adoption of PAE as an effective treatment option. The growing geriatric population, which is more susceptible to prostatic conditions, further propels the demand for PAE. Collectively, these factors are expected to significantly boost the market in the coming years.

Growth Factor of the Market

The growth of the Prostatic Artery Embolization market is primarily influenced by the rising incidence of prostatic diseases, particularly BPH, which affects a significant proportion of men over the age of 50. As the population ages, the demand for effective and less invasive treatment options continues to rise. In addition, the development of innovative embolic agents and delivery systems has enhanced the outcomes of PAE, making it a preferred choice among urologists. The shift towards outpatient procedures also reflects a change in patient preferences, as individuals seek treatments that allow for quicker recovery and reduced hospital stays. Moreover, the increasing adoption of advanced imaging technologies plays a pivotal role in the successful execution of PAE, thereby expanding its applicability and acceptance in clinical practice. Overall, these factors are instrumental in driving market growth and increasing the accessibility of PAE to a broader patient demographic.

Key Highlights of the Market

• The PAE market is expected to experience significant growth, driven by technological advancements and increasing patient awareness.
• North America currently holds the largest market share, attributed to its superior healthcare infrastructure.
• Microcatheters are projected to be the fastest-growing product type due to their critical role in the embolization process.
• Benign Prostatic Hyperplasia remains the leading application segment, reflecting the high prevalence of the condition.
• There is a notable trend towards minimally invasive procedures, with patients increasingly preferring outpatient services for PAE.

By Product Type

Microcatheters:

Microcatheters are crucial tools in the PAE procedure, allowing for precise delivery of embolic agents into the prostatic arteries. Their small diameter enables access to the complex vascular structures surrounding the prostate, which is essential for effective embolization. The increasing emphasis on precision medicine and minimally invasive techniques has driven the demand for specialized microcatheters that offer enhanced maneuverability and control during the procedure. With advancements in catheter technology, these devices are being designed to improve durability and reduce the risk of complications, contributing to their growing market share. As more urologists adopt PAE as a treatment modality, the reliance on high-quality microcatheters is expected to rise significantly, further solidifying their position in the market.

Guidewires:

Guidewires play a pivotal role in the PAE procedure, acting as a facilitator for the navigation and positioning of microcatheters within the vascular system. The demand for advanced guidewires is increasing due to their ability to enhance the safety and efficiency of embolization procedures. These wires are engineered for optimal flexibility, torque response, and navigability, which are essential for reaching the prostatic arteries effectively. As the focus on patient safety continues to rise, the use of high-quality guidewires that minimize the risk of vascular trauma is becoming more common. Consequently, the guidewire segment is expected to witness sustained growth as healthcare providers aim to improve patient outcomes through the adoption of superior tools in the PAE process.

Embolic Agents:

Embolic agents are key components in the PAE procedure, designed to obstruct blood flow to the prostate and facilitate symptom relief. The market for embolic agents is expanding due to the ongoing development of innovative materials that provide enhanced efficacy and safety profiles. Various types of embolic agents, including polyvinyl alcohol particles and gelatin microspheres, are gaining traction for their ability to achieve targeted embolization while minimizing adverse effects. As research continues to innovate in this field, the introduction of novel embolic materials that offer improved biocompatibility and controlled particle size is expected to drive market growth. This segment's advancements are crucial as they directly influence the success rates of PAE, thereby reinforcing the demand for effective embolic agents.

Coils:

Coils are utilized in PAE to occlude blood vessels, effectively reducing blood flow to the prostate. This product type has gained popularity due to its proven effectiveness and ease of use in procedure protocols. Coils come in various sizes and configurations, allowing for tailored treatment approaches based on individual patient anatomy and condition severity. The ability to provide immediate results and rapid symptom relief has made coils a favored choice among interventional radiologists and urologists. Furthermore, ongoing advancements in coil technology, such as the development of bioresorbable coils, are anticipated to further enhance their application in PAE, ensuring their continued relevance and growth within the market.

Others:

The "Others" category encompasses various ancillary devices and instruments utilized during the PAE procedure, such as vascular access tools, contrast media, and imaging supplies. The growth of this segment is largely driven by the increasing demand for comprehensive treatment solutions that enhance the overall efficacy of PAE. The integration of advanced imaging technologies into the embolization process has led to improved procedural outcomes, making these auxiliary products more critical than ever. As healthcare facilities strive to optimize their interventional radiology services, investments in a broader range of support devices are expected to rise, propelling the growth of this segment in the PAE market.

By Application

Benign Prostatic Hyperplasia:

Benign Prostatic Hyperplasia (BPH) is the leading application driving the Prostatic Artery Embolization market. This condition, characterized by an enlarged prostate, affects millions of men globally, leading to urinary symptoms that can significantly impair quality of life. PAE has emerged as a transformative treatment option for BPH, offering a minimally invasive alternative to traditional surgical interventions. As awareness of PAE's benefits grows among both patients and healthcare providers, its adoption for BPH management is expected to rise. The efficacy of PAE in alleviating urinary symptoms and its favorable safety profile contribute to its increasing acceptance as a frontline therapy, further solidifying its dominant position in the application segment.

Prostate Cancer:

Prostate cancer is another significant application area for Prostatic Artery Embolization, offering a targeted approach to managing tumor growth while preserving surrounding healthy tissue. As the incidence of prostate cancer continues to rise globally, there is an increasing demand for effective treatment modalities that mitigate the adverse effects typically associated with conventional therapies. PAE serves as a promising solution, providing oncologists with a minimally invasive option to control tumor vascularization and potentially improve patient outcomes. The integration of PAE into prostate cancer treatment protocols is expected to grow, particularly in patients who are not candidates for surgery or those seeking alternatives to more aggressive treatments.

Hematuria:

Hematuria, or the presence of blood in urine, can be indicative of various underlying urological conditions, including malignancies and vascular abnormalities. PAE is gaining traction as a viable treatment option for managing hematuria, particularly when conventional therapies have failed. The ability of PAE to precisely occlude bleeding vessels while preserving normal renal function makes it a favorable choice among urologists. As healthcare providers continue to explore less invasive treatment alternatives, the role of PAE in managing hematuria is anticipated to expand, thereby contributing to the overall growth of the market. The focus on patient-centered care and the minimization of procedural risks align well with the objectives of PAE in addressing this complex clinical scenario.

Pelvic Pain:

Pelvic pain, often associated with vascular abnormalities or chronic conditions, poses a significant treatment challenge. PAE has emerged as a novel method to address pelvic pain by embolizing blood vessels supplying painful regions. This application is particularly relevant in cases where other treatments have failed to provide relief. The ability of PAE to offer targeted pain management while minimizing systemic side effects positions it as a valuable tool in the interventional radiology arsenal. Growing recognition of the effectiveness of PAE in alleviating pelvic pain is likely to enhance its adoption, thus contributing positively to market dynamics.

Others:

The “Others” category in applications includes various urological conditions where PAE may be considered as a treatment option. These can range from conditions like pelvic organ prolapse to more complex vascular issues. The versatility of PAE in addressing multiple urological conditions is a significant factor driving its market growth. As research continues to expand the understanding of PAE's potential applications, its role in treating diverse urological issues is expected to evolve, thereby broadening the scope of this segment within the market.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for Prostatic Artery Embolization procedures, given their comprehensive resources and specialized medical staff. Many hospitals are equipped with advanced imaging technologies and interventional radiology departments that facilitate the execution of PAE. The increasing number of patients being treated for prostatic diseases within hospital settings reflects the trust placed in these institutions by patients and healthcare professionals. Furthermore, hospitals often possess the infrastructure necessary for the management of potential complications, thereby enhancing patient safety during and after the procedure. The ongoing investments in hospital-based interventional radiology services are expected to further solidify their leading position in the distribution channel segment.

Ambulatory Surgical Centers:

Ambulatory Surgical Centers (ASCs) are gaining popularity as a distribution channel for Prostatic Artery Embolization due to their focus on providing outpatient services. These centers allow patients to undergo PAE with the advantage of reduced recovery times and minimal hospital stays. The trend toward outpatient procedures aligns with patient preferences for less invasive treatments that offer the potential for quicker return to daily activities. As ASCs continue to enhance their service offerings and improve procedural efficiencies, they are expected to capture a larger share of the PAE market, driven by the increasing demand for patient-centered care.

Specialty Clinics:

Specialty clinics focused on urology and interventional radiology are pivotal players in the Prostatic Artery Embolization market. These clinics often provide tailored treatment options and possess specialized expertise in managing prostatic conditions. The growth of specialty clinics is fueled by the rising demand for focused care and the increasing recognition of PAE as an effective treatment modality. Patients seeking reliable and expert care are more likely to gravitate toward clinics that specialize in PAE, contributing to the market expansion in this distribution channel. Moreover, as these clinics continue to innovate and improve their services, their role in the PAE landscape is projected to grow significantly.

Others:

The "Others" segment in distribution channels includes various healthcare settings such as rehabilitation centers and telemedicine platforms that offer PAE consultations or follow-up care. Although relatively smaller in market share compared to hospitals and ASCs, these alternative distribution channels are becoming increasingly relevant in the evolving healthcare landscape. The rise of telehealth and virtual consultations has paved the way for expanded access to PAE services, allowing patients to receive expert advice and management from the comfort of their homes. As the healthcare ecosystem continues to adapt to new technologies and patient needs, the potential for growth within this segment is noteworthy.

By Ingredient Type

Polyvinyl Alcohol Particles:

Polyvinyl Alcohol (PVA) particles are widely utilized as embolic agents in Prostatic Artery Embolization procedures. These particles are particularly favored due to their biocompatibility and ability to achieve targeted occlusion of the prostatic blood supply. PVA particles come in varying sizes, allowing for customized treatment approaches based on individual patient anatomy and the specific vascular structures involved. The ability to achieve effective embolization while minimizing off-target effects makes PVA particles a staple choice among interventional radiologists. With ongoing research into improving the efficacy and safety of PVA particles, their market share in the PAE segment is anticipated to remain strong.

Tris-acryl Gelatin Microspheres:

Tris-acryl gelatin microspheres serve as another popular choice of embolic agent in the PAE procedure. These microspheres have demonstrated excellent performance in achieving controlled embolization, allowing for precise targeting of the prostatic arteries. The unique properties of these microspheres, including their ability to be loaded with contrast agents, enhance visualization during the procedure and improve overall treatment outcomes. As awareness continues to grow regarding the efficacy of tris-acryl gelatin microspheres, their adoption in PAE is expected to increase, making them a significant player in the ingredient type segment.

Embosphere Microspheres:

Embosphere microspheres are renowned for their uniformity and high level of precision in embolization procedures. Widely recognized for their safety profile and effective occlusion capabilities, these microspheres are increasingly being utilized in PAE to treat conditions such as BPH and prostate cancer. The reliance on Embosphere microspheres aligns with the growing trend toward minimally invasive techniques that prioritize patient safety and comfort. As clinical evidence supporting their efficacy continues to emerge, the market presence of Embosphere microspheres within the PAE ingredient type segment is expected to expand further.

Onyx Liquid Embolic System:

The Onyx Liquid Embolic System represents a cutting-edge option for PAE, offering a unique approach to vascular occlusion. This liquid embolic agent allows for precise and controlled delivery into the targeted blood vessels, ensuring effective embolization of the prostatic arteries. The versatility of the Onyx system makes it particularly advantageous in challenging vascular anatomies, where traditional solid agents may fall short. As more interventional radiologists gain experience with this innovative embolic option, its utilization in PAE is likely to increase, positioning it as a key player in the ingredient type market.

Others:

The "Others" category in ingredient types includes various alternative embolic materials that are utilized in specific cases based on clinical requirements. These may consist of agents like n-butyl cyanoacrylate or gel foam, which can be opted for depending on the unique anatomical and pathological contexts of the patient. As research continues to unveil the potential of various embolic agents in PAE, this segment is expected to witness gradual growth, driven by the increasing demand for personalized and effective treatment solutions in urology.

By Region

North America currently dominates the Prostatic Artery Embolization market, accounting for over 40% of the total market share, primarily due to advanced healthcare infrastructure, high levels of R&D investment, and a robust presence of key industry players. The United States, being a frontrunner in healthcare technology and innovation, has facilitated the widespread adoption of PAE among urologists and interventional radiologists. Furthermore, an increasing number of clinical studies validating the efficacy of PAE in treating prostatic conditions is expected to bolster market growth within this region. With a projected CAGR of 9% over the next decade, North America is likely to maintain its leading position in the global PAE market.

Europe ranks second in terms of market share, benefiting from extensive healthcare systems and rising patient awareness regarding PAE as an alternative therapy for BPH and prostate cancer. The European market is characterized by a growing number of specialized clinics offering PAE procedures, which are increasingly sought after by patients looking for effective solutions to prostatic issues. Additionally, the regulatory framework supporting medical innovations further enhances the growth potential of the PAE market in the region. The Asia Pacific region is emerging as a high-growth area, driven by an increase in the aging population and a rise in prostatic diseases, with a projected CAGR of 10.5% between 2025 and 2035, indicating significant opportunities for market expansion.

Opportunities

The Prostatic Artery Embolization market presents numerous opportunities for growth, particularly in emerging economies where the demand for advanced medical procedures is on the rise. As healthcare systems in these regions continue to evolve, there is an increasing push towards adopting minimally invasive techniques that offer quicker recovery times and lower complication rates. This shift is particularly significant in countries with rapidly aging populations, where the prevalence of prostatic diseases is expected to soar. Furthermore, the integration of technology and telemedicine in healthcare delivery provides an excellent opportunity for PAE providers to expand their reach and offer consultations and follow-up care remotely. By leveraging these developments, companies can enhance patient awareness and access to PAE, ultimately driving market growth.

Additionally, the trend towards personalized medicine offers significant opportunities for the PAE market. As more healthcare providers recognize the importance of tailored treatment plans based on individual patient needs, the demand for advanced embolic agents and delivery systems will likely increase. This demand will stimulate innovation and R&D efforts focused on improving the safety and efficacy of PAE procedures. Collaborations between medical device manufacturers, research institutions, and healthcare providers can facilitate the development of novel embolic materials and techniques that improve patient outcomes. Such strategic partnerships are vital for harnessing the full potential of the PAE market, creating a conducive environment for sustained growth and expansion.

Threats

Despite the promising growth prospects of the Prostatic Artery Embolization market, there are notable threats that could impede its progress. One of the primary concerns is the regulatory landscape surrounding medical devices and procedures, which can vary significantly from region to region. Changes in regulatory requirements or approval processes may create hurdles for companies looking to introduce innovative embolic agents or technologies. Additionally, increasing competition from alternative treatment modalities, such as medication or surgical interventions, poses a challenge to the market. Patients often weigh the risks and benefits of various treatment options, and if alternative therapies prove to be more accessible or affordable, they may opt for those instead. This competitive pressure necessitates continuous innovation and effective marketing strategies to position PAE as the preferred treatment option.

Another significant threat to the market is the potential for adverse events or complications associated with PAE procedures. Although PAE is generally considered safe, any incidents of complications can negatively affect patient trust and acceptance of the procedure. Healthcare providers must emphasize the importance of proper patient selection and procedural proficiency to minimize risks. In addition, the ongoing rise of telehealth and remote consultations could also disrupt traditional service delivery models, as patients increasingly seek alternative avenues for treatment. To stay competitive, PAE providers will need to adapt to these changes and ensure they are offering the highest standards of care.

Competitor Outlook

• Boston Scientific Corporation
• Medtronic plc
• Terumo Corporation
• Cook Medical
• Merit Medical Systems, Inc.
• AngioDynamics, Inc.
• Philips Healthcare
• Cardinal Health, Inc.
• Stryker Corporation
• Abbott Laboratories
• Johnson & Johnson
• Hologic, Inc.
• BTG International Ltd.
• Asahi Intecc Co., Ltd.
• Medi-Globe Technologies

The competitive landscape of the Prostatic Artery Embolization market is characterized by the presence of several key players actively developing and marketing innovative products. Companies such as Boston Scientific Corporation and Medtronic plc are at the forefront, investing heavily in R&D to enhance the efficacy and safety of embolic materials used in PAE. These multinational corporations leverage their extensive distribution networks and established brand recognition to maintain a competitive edge in the market. Additionally, the focus on strategic partnerships and mergers and acquisitions allows these companies to expand their product portfolios and enhance their market presence.

Other notable players, such as Cook Medical and Terumo Corporation, are recognized for their specialized product offerings and commitment to improving patient outcomes through innovative technologies. Cook Medical, for instance, has been active in developing advanced microcatheters and embolic agents that cater to the specific needs of interventional radiologists. Terumo Corporation, with its strong emphasis on quality and safety, has developed a range of embolic products that are gaining traction in the PAE market. As companies continue to innovate and refine their product offerings, competition is expected to intensify, driving further advancements in the PAE landscape.

Emerging players and startups also play a crucial role in the competitive dynamics of the Prostatic Artery Embolization market. These companies often focus on niche areas of embolization technology, offering specialized products that cater to unique patient needs. Their agility and ability to rapidly develop novel solutions can disrupt established players and introduce new standards of care. Overall, the competitive landscape is vibrant, with continuous advancements and a focus on improving patient outcomes and procedural efficiencies driving the market forward.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Cook Medical
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Hologic, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic plc
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Johnson & Johnson
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Philips Healthcare
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Terumo Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 AngioDynamics, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Stryker Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Cardinal Health, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Asahi Intecc Co., Ltd.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 BTG International Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Medi-Globe Technologies
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Merit Medical Systems, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Boston Scientific Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Prostatic Artery Embolization Market, By Application
    • 6.1.1 Benign Prostatic Hyperplasia
    • 6.1.2 Prostate Cancer
    • 6.1.3 Hematuria
    • 6.1.4 Pelvic Pain
    • 6.1.5 Others
  • 6.2 Prostatic Artery Embolization Market, By Product Type
    • 6.2.1 Microcatheters
    • 6.2.2 Guidewires
    • 6.2.3 Embolic Agents
    • 6.2.4 Coils
    • 6.2.5 Others
  • 6.3 Prostatic Artery Embolization Market, By Ingredient Type
    • 6.3.1 Polyvinyl Alcohol Particles
    • 6.3.2 Tris-acryl Gelatin Microspheres
    • 6.3.3 Embosphere Microspheres
    • 6.3.4 Onyx Liquid Embolic System
    • 6.3.5 Others
  • 6.4 Prostatic Artery Embolization Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Ambulatory Surgical Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Prostatic Artery Embolization Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Prostatic Artery Embolization market is categorized based on

By Product Type

• Microcatheters
• Guidewires
• Embolic Agents
• Coils
• Others

By Application

• Benign Prostatic Hyperplasia
• Prostate Cancer
• Hematuria
• Pelvic Pain
• Others

By Distribution Channel

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Ingredient Type

• Polyvinyl Alcohol Particles
• Tris-acryl Gelatin Microspheres
• Embosphere Microspheres
• Onyx Liquid Embolic System
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Boston Scientific Corporation
• Medtronic plc
• Terumo Corporation
• Cook Medical
• Merit Medical Systems, Inc.
• AngioDynamics, Inc.
• Philips Healthcare
• Cardinal Health, Inc.
• Stryker Corporation
• Abbott Laboratories
• Johnson & Johnson
• Hologic, Inc.
• BTG International Ltd.
• Asahi Intecc Co., Ltd.
• Medi-Globe Technologies